Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2004

View Archived Issues

Tarceva accepted onto FDA Pilot 1 Program

Xenon Genetics changes name to Xenon Pharmaceuticals

Large Scale Biology and the U. of Louisville collaborate on HPV-associated cancers

Phase Ic results of PYY3-36 nasal spray for obesity

Alcon files second portion of Retaane rolling NDA

Enrollment under way in two phase III Leukine studies for Crohn's disease

New phase II study of Telcyta combination front-line treatment of NSCLC

Merck & Co. and Alnylam collaborate on RNAi therapeutics for ocular diseases

BioXell acquires from Roche rights to new indications for BXL-628

Eisai launches Apnission in Japan

Acetylcholinesterase inhibitor ITH-4012 shows calcium promoting and neuroprotective activity

Centocor and Fujisawa discontinue codevelopment of abciximab in Japan

CoTherix submits NDA for Ventavis

OPi and Vaccinex establish antibody collaboration

European orphan drug designation recommended for Surfaxin

Striant SR submitted for mutual recognition procedure in Europe

Mitsubishi Pharma describes series of cyclic amide derivatives

COX-2 inhibitors presented by CJ Corporation

Achillion Pharmaceuticals claims inhibitors of hepatitis C virus replication

Ubiquitination inhibitors in early development at Rigel

BMS scientists prepare and test novel selective androgen receptor modulators

Sumitomo discloses agents for fibrosis in patent literature

Modafinil beneficial in patients with schizophrenia

Development of LJP-1082 and LJP-394 reviewed

Novel potent and selective T-type calcium channel blockers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...